

EXACT SCIENCES CORP

FORM 8-K (Unscheduled Material Events)

Filed 2/8/2005 For Period Ending 2/7/2005

Address	100 CAMPUS DRIVE MARLBOROUGH, Massachusetts 01752
Telephone	508-683-1200
CIK	0001124140
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **February 7, 2005**

EXACT SCIENCES CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

000-32179

(Commission File Number)

02-0478229

(IRS Employer Identification No.)

100 Campus Drive, Marlborough, Massachusetts

(Address of Principal Executive Offices)

01752

(Zip Code)

Registrant's telephone number, including area code: **(508) 683-1200**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

Item 7.01 Regulation FD Disclosure.

On February 7, 2005, Exact Sciences Corporation issued a press release, a copy of which is being furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits:

99.1 Press Release issued by the Registrant on February 7, 2005, furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXACT Sciences Corporation

February 7, 2005

By: /s/ Don Hardison
Don Hardison
President and CEO

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release issued by the Registrant on February 7, 2005, furnished herewith.

4

Exhibit 99.1



Press Release

FOR IMMEDIATE RELEASE

For further information:

Media:

Kerry Beth Daly
Fleishman-Hillard
P: (617) 267-8223
E: dalyk@fleishman.com

Investor Relations and

Corporate Communications:

Amy Hedison
EXACT Sciences
P: (508) 683-1252
E: ahedison@exactsciences.com

**EXACT SCIENCES TO WEBCAST PRESENTATION AT
MERRILL LYNCH 2005 GLOBAL PHARMACEUTICAL,
BIOTECHNOLOGY AND MEDICAL DEVICE CONFERENCE**

Marlborough, Mass. – February 7, 2005 – EXACT Sciences Corporation (NASDAQ: EXAS) announced today that its presentation at the Merrill Lynch 2005 Global Pharmaceutical, Biotechnology and Medical Device Conference will be webcast live.

Don Hardison, EXACT Sciences' President and CEO, and Anthony Shuber, EXACT Sciences' Chief Technology Officer, are scheduled to deliver a presentation on Thursday, February 10, 2005 at 10:30 a.m. (Eastern Standard Time) at the Grand Hyatt Hotel in New York City. The presentation will discuss, among other things, the Company's applied research and commercial strategies, and the Company's focus of resources for 2005. The webcast of the presentation may be accessed at EXACT Sciences' website, www.exactsciences.com, through the Investor Relations page. An archived version of the webcast will be available for 14 days following the live presentation.

About EXACT Sciences Corporation

EXACT Sciences Corporation is a leader in rapidly applying genomics knowledge to develop effective, patient-friendly screening methods to detect cancer early, to assist physicians in saving patients' lives. Its first commercial test, PreGen-Plus™, is used for screening colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than 20 years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies will enable early detection of colorectal cancer so that more people can be effectively treated. Founded in 1995, EXACT Sciences is based in Marlborough, Mass. Detailed information on EXACT Sciences and PreGen-Plus can be found on the World Wide Web at www.exactsciences.com and www.pregenplus.com.

####

End of Filing

Powered By **EDGAR**
Online

© 2005 | EDGAR Online, Inc.